Minimal Residual Disease (MRD) As A Predictive Biomarker/Endpoint for Novel Drug Development Read more about Minimal Residual Disease (MRD) As A Predictive Biomarker/Endpoint for Novel Drug Development
Dual approach using proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients Read more about Dual approach using proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
Custom PhenoImager™ fluorescent multiplex IHC panel identifies mature tertiary lymphoid structures in colorectal cancer Read more about Custom PhenoImager™ fluorescent multiplex IHC panel identifies mature tertiary lymphoid structures in colorectal cancer
Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP) Read more about Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP)
Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients Read more about Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
Plasma first: Accelerating lung cancer diagnosis through liquid biopsy Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy
Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) Read more about Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)
Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC Read more about Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC
Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma